The Largest Companies in Medical Laboratories Industry Value and Market Capitalization, Revenue, Income, Number of Employees - CSIMarket
Healthcare Sector

The Largest Companies in Medical Laboratories Industry

Explore the largest companies by market capitalization, revenue, income, and employees within the Medical Laboratories industry

Classification: SIC NAICS ISIC Available under Commercial License
TTM data as of: September 28, 2026
Total Market Cap
$ 386B
Billions USD (aggregate)
Total Revenue (TTM)
$ 119B
Trailing twelve months
Total Net Income (TTM)
$ 6B
Trailing twelve months
Total Employees
467,233
Headcount (aggregate)
API endpoints for this dataset
https://api.csimarket.com/api/v1/industries/805/list
Programmatic access for models, analytics, and integration workflows.

Explore the largest companies by market capitalization, revenue, income, and employees within the Medical Laboratories industry

Company Market Cap
(Millions)
Revenue TTM
(Millions)
Net Income TTM
(Millions)
Employees
Total Medical Laboratories Industry $ 386,018 $ 119,489 $ 6,397 467,233
49 more companies available

Sign in to unlock the full Medical Laboratories Industry dataset.

Industry Benchmarking Dataset for Institutional Use

Commercial

The data presented above is part of our institutional-grade Industry Benchmarking Dataset, designed for integration into credit risk models, AML/KYC frameworks, portfolio analytics, and internal banking systems. The full dataset is available under a Commercial License, with delivery via API or bulk CSV datasets.

Advanced Metrics & Analytics
  • Multi-year CAGRs & growth acceleration signals
  • Volatility measures & trend stability indicators
  • Cross-sectional percentiles (median, p25, p75)
  • Dispersion metrics (std deviation, spread)
  • Composite scores (growth quality, distress risk)
Institutional Use Cases
  • Credit underwriting & peer benchmarking
  • AML / KYC financial validation
  • Portfolio monitoring & risk tracking
  • Quantitative modeling & factor construction
  • Sector risk & supply chain exposure analysis
Data Delivery
API Access
Real-time endpoints delivering data into risk engines, models, and internal systems.
Bulk CSV Datasets
Pre-structured datasets optimized for direct ingestion into data warehouses, enabling large-scale modeling, backtesting, and historical analysis.
Licensing
Available under institution-grade licensing frameworks with defined usage rights, distribution scope, and integration permissions, supporting internal use, client reporting, and enterprise-wide deployment.
CSIMarket - Industry Benchmarking Data - Per Industry

Institutional-grade industry datasets
in standardized CSV format

Pre-cleaned, audit-ready benchmarking data for this industry - 6 CSV files covering profitability, growth, valuation, efficiency, management effectiveness, and financial strength. Each file delivers 20 quarters and 5 fiscal years of history, with statistical distributions and composite scores per period.

6CSV files
3,880Quarterly endpoints
360Annual endpoints
20Quarters of history
5Fiscal years
Profitability
37 quarterly - 10 annual indicators 790 endpoints ?
Growth
31 quarterly - 7 annual indicators 1,455 endpoints ?
Valuation
29 quarterly - 10 annual indicators 630 endpoints ?
Efficiency
16 quarterly - 12 annual indicators 380 endpoints ?
Management
20 quarterly - 16 annual indicators 480 endpoints ?
Fin. Strength
21 quarterly - 17 annual indicators 505 endpoints ?
Total dataset size - across 110 industries
Quarterly data points
388,000
3,880 × 110 industries
Annual data points
36,000
360 × 110 industries
Industries covered
110
all sectors
Total data points
424,000
quarterly + annual
Industry classification systems supported
CSIMarket Proprietary classification optimized for financial benchmarking and industry analytics
NAICS North American Industry Classification System - used by U.S., Canada & Mexico federal agencies
SIC Standard Industrial Classification - legacy system used by the SEC and financial regulators
ISIC International Standard Industrial Classification - UN framework for global economic comparison
Dataset 1 - Profitability Benchmarks

Margin benchmarks across the full industry distribution

Gross, operating, EBITDA, pre-tax, net, and free cash flow margins - delivered as TTM, quarterly, and annual series with P25 / median / P75 / standard deviation for every reporting period.

Net margin (TTM Q4)
7.44%
+2.11pp vs prior yr
Gross margin
10.44%
industry avg
FCF margin
13.66%
strong
Companies reported
31
Q4 2025
Data coverage per industry
Quarterly indicators
37
metrics per period
Annual indicators
10
fiscal year metrics
Quarterly endpoints
740
20 quarters × 37
Annual endpoints
50
5 fiscal years × 10
Gross, operating, EBITDA, net & FCF margins
TTM, quarterly & fiscal year series
P25 / median / P75 / std dev per period
YoY margin change & acceleration
Effective tax rate & pre-tax margin
Profitability composite score (0–100)
Report preview - Profitability Benchmarks - Aerospace & Defense
Profitability Benchmarks report sample
Dataset 2 - Growth Dynamics

Revenue, income & cash flow growth across 13+ line items

Industry-level growth benchmarks for every major P&L and cash flow line - with breadth indicators showing what share of companies posted positive growth, acceleration metrics, and rolling TTM comparisons.

Revenue growth (TTM Q4)
12.84%
improving
Net income growth
18.45%
above revenue
FCF growth
13.60%
strong
EPS acceleration
+3.69pp
vs prior TTM
Data coverage per industry
Quarterly indicators
31
metrics per period
Annual indicators
7
fiscal year metrics
Quarterly endpoints
1,420
20 quarters × 31
Annual endpoints
35
5 fiscal years × 7
Revenue, gross, EBIT & operating income growth
Net income, EPS (basic & diluted) growth
FCF, net cash flow & CapEx growth
Breadth: % of companies with positive growth
QoQ, YoY, TTM & 3-year CAGR
Growth composite score (0–100)
Report preview - Growth Dynamics - Aerospace & Defense
Growth Dynamics report sample
Dataset 3 - Valuation Multiples

Industry valuation multiples with 5-year context & Z-scores

P/E, P/S, P/FCF, P/Book, EV/EBITDA - current and trailing - with five-year averages, percentile ranks, Z-scores, and a composite valuation score to place the industry in historical context.

P/E ratio (current)
22.4x
vs 5yr avg 14.2x
EV/EBITDA (TTM)
13.1x
P25–P75: 4.5x–20.4x
Earnings yield
4.46%
attractive
Composite val. score
61.7
moderately valued
Data coverage per industry
Quarterly indicators
29
metrics per period
Annual indicators
10
fiscal year metrics
Quarterly endpoints
580
20 quarters × 29
Annual endpoints
50
5 fiscal years × 10
P/E, P/S, P/CF, P/FCF, P/Book multiples
EV/EBITDA & EV/Sales (current & TTM)
5-year historical average per multiple
Z-scores & percentile ranks
Earnings yield & FCF yield
Composite valuation score (0–100)
Report preview - Valuation Multiples - Aerospace & Defense
Valuation Multiples report sample
Dataset 4 - Operational Efficiency

Productivity, turnover ratios & cash conversion benchmarks

Revenue and income per employee, asset and receivables turnover, days sales outstanding, days inventory, days payables, and the full cash conversion cycle - benchmarked across the industry distribution.

Revenue / employee
$487K
improving
Asset turnover
0.61x
P75: 0.80x
Cash conv. cycle
113 days
above avg
Efficiency score
68.7
composite 0–100
Data coverage per industry
Quarterly indicators
16
metrics per period
Annual indicators
12
fiscal year metrics
Quarterly endpoints
320
20 quarters × 16
Annual endpoints
60
5 fiscal years × 12
Revenue & net income per employee
Asset, receivables & inventory turnover
DSO, DIO, DPO & cash conversion cycle
Working capital per revenue
YoY & TTM trend for all metrics
Efficiency composite score (0–100)
Report preview - Operational Efficiency - Aerospace & Defense
Operational Efficiency report sample
Dataset 5 - Management Effectiveness

ROA, ROE, ROIC & DuPont decomposition benchmarks

Return metrics measuring how effectively management allocates capital - with incremental ROIC, DuPont decomposition, FCF quality indicators, and a composite management effectiveness score across the industry.

Return on assets
5.05%
vs 4.44% prior
Return on equity
14.22%
improving
ROIC (TTM)
9.77%
P75: 12.4%
Effectiveness score
72.4
composite index
Data coverage per industry
Quarterly indicators
20
metrics per period
Annual indicators
16
fiscal year metrics
Quarterly endpoints
400
20 quarters × 20
Annual endpoints
80
5 fiscal years × 16
ROA, ROE & ROIC - TTM & quarterly
Incremental ROIC & capital intensity
DuPont 3-factor decomposition
FCF conversion quality metrics
P25 / median / P75 / std dev per metric
Management effectiveness composite (0–100)
Report preview - Management Effectiveness - Aerospace & Defense
Management Effectiveness report sample
Dataset 6 - Financial Strength

Leverage, liquidity & debt coverage across the industry

Debt-to-equity, interest and debt coverage, quick ratio, working capital, leverage ratios - full distribution statistics - in standardized, audit-ready format suited for credit workflows, compliance, and ESG reporting.

Debt / equity (TTM)
1.44x
above industry avg
Interest coverage
8.32x
comfortable
Quick ratio
0.91x
vs P75 1.18x
Fin. strength score
58.4
composite 0–100
Data coverage per industry
Quarterly indicators
21
metrics per period
Annual indicators
17
fiscal year metrics
Quarterly endpoints
420
20 quarters × 21
Annual endpoints
85
5 fiscal years × 17
Quick ratio & working capital ratio
Total & LT debt-to-equity
Leverage & tangible leverage ratios
Interest & debt coverage ratios
P25 / median / P75 / std dev per metric
Financial strength composite score (0–100)
Report preview - Financial Strength - Aerospace & Defense
Financial Strength report sample
Methodology
1. Data Coverage & Universe
Structured dataset built from publicly listed companies, classified across industries, sectors, and total market using CSIMarket, NAICS, SIC, and ISIC frameworks.

Includes up to 5 years of quarterly data (TTM, quarterly, annualized) with continuous updates during earnings cycles.

Coverage transparency includes total companies, reported companies per metric, and coverage ratios.
2. Aggregation Methodology
Industry metrics are calculated using aggregated financial statements, not averages.

Sum-based aggregation is applied to revenue, income, assets, and debt, with market-cap weighting for valuation metrics and TTM normalization to reduce seasonality.

Example: P/E = Total Market Cap ÷ Total Net Income.
3. Ratio Construction
Ratios are standardized and calculated at the company level, then benchmarked across industries.

Covers profitability, valuation, financial strength, efficiency, and growth metrics including margins, ROE, EV multiples, leverage ratios, and CAGR growth measures.
4. Distribution Analytics
Full cross-sectional distribution analysis includes median (P50), quartiles (P25/P75), standard deviation, and interquartile range.

Enables detection of outliers, dispersion, and structural differences within industries.
5. Percentile Rankings
Metrics are normalized into 0–100 percentile rankings using cross-industry PERCENT_RANK().

Direction is adjusted by metric (higher = better for growth/profitability, lower = better for leverage/risk).

Used for benchmarking, factor models, and relative analysis.
6. Volatility & Trend Metrics
Includes volatility (e.g., 8-quarter standard deviation), trend slopes, and growth consistency metrics.

Captures earnings stability, margin durability, and cyclicality across industries.
7. Composite Scores
Multi-factor composite scores (0-100 scale) combine normalized inputs using weighted models.

Includes valuation, growth quality, financial strength, and distress risk scores.
8. Data Quality Controls
Data undergoes standardization, outlier detection, consistency checks, and coverage-based filtering.

Reporting counts and coverage ratios are provided for transparency.
9. Update Frequency
Dataset is continuously updated during earnings seasons.

TTM metrics are recalculated with each new filing, reflecting the most recent reported data.
10. Use Cases
Designed for credit risk analysis, AML/KYC validation, portfolio monitoring, quantitative modeling, and benchmarking workflows.
11. Licensing & Access
Free preview available for evaluation. Full dataset access requires a commercial license.

API and bulk delivery options available for system integration.

Recent News from The Largest Companies in Medical Laboratories Industry

Business Update
Guardant Health, Inc. (NASDAQ GH), a prominent player in the precision oncology landscape, is set to presen...

Guardant Health Showcases Innovative Liquid Biopsy Research at SABCS Amid Strong Revenue Growth Guardant Health, Inc. (NASDAQ: GH), a prominent player in the precision oncology landscape, is set to present 14 abstracts at the upcoming 2025 San Antonio Breast Cancer Symposium (SABCS), scheduled for December 9-12, 2025. This presentation will highlight the ...

Dec 5, 2025 • Medical Laboratories Industry
GH
Clinical Study
Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Ant...

Advancements in Targeted Oncology: An Overview of Celcuity s Latest Findings and Future Directions Breast cancer remains one of the most prevalent and challenging malignancies to treat, requiring continuous efforts in research and development of new therapeutic strategies. Celcuity Inc., a clinical-stage biotechnology company, has positioned itself at th...

Nov 27, 2025 • Medical Laboratories Industry
CELC
Business Update
Personalis Medicare Coverage Sparks Hope Amidst Competitive Challenges in Precision Oncology

In a landmark development for breast cancer patients and the realm of precision oncology, Personalis, Inc. (Nasdaq: PSNL) has announced Medicare coverage for its ultrasensitive NeXT Personal test, designed for monitoring cancer recurrence. This announcement represents a significant advancement in cancer surveillance, particularly for Medicare beneficiarie...

Nov 10, 2025 • Medical Laboratories Industry
PSNL
Business Update
Exact Sciences Transforms Liver Cancer Detection ALTUS Study Unveils Superior Performance of Oncoguard Liver Bl...

MADISON, Wis. Exact Sciences Corp. (NASDAQ: EXAS), a recognized leader in the field of cancer screening and diagnostic tests, has announced unprecedented results from its landmark ALTUS study (NCT: 05064553). These pivotal clinical validation findings highlight the significant potential of the company’s Oncoguard Liver blood test in transforming the ...

Nov 7, 2025 • Medical Laboratories Industry
EXAS
Business Update
Augmenting Transplant Care CareDx Unveils Groundbreaking Innovations and Research at ASN Kidney Week 2025 and Wo...

Revolutionizing Transplant Care: CareDx Unveils Groundbreaking Innovations and Research at ASN Kidney Week 2025 and World Transplant CongressIn the rapidly advancing field of transplant medicine, CareDx, Inc. (Nasdaq: CDNA) dubbed The Transplant Company has positioned itself as a leader in precision medicine, particularly for kidney transplant patients. ...

Nov 6, 2025 • Medical Laboratories Industry
CDNA
Business Update
Guardant Healths Shield Test Sets New Standard in Colorectal Cancer Screening with 95% Adherence, Earning Globa...

PALO ALTO, Calif. In a landmark development for precision oncology, Guardant Health, Inc. (Nasdaq: GH) has announced groundbreaking findings related to its Shield blood test for colorectal cancer (CRC) screening. A recent real-world study published in Current Medical Research and Opinion indicates that the Shield test boasts a remarkable patient adher...

Nov 6, 2025 • Medical Laboratories Industry
GH
Business Update
Guardant Health Eyes $250 Million Growth Surge with New Public Offering,

Guardant Health s Strategic Move: A $250 Million Public Offering to Fuel GrowthIn a significant move, Guardant Health, Inc., a trailblazer in precision oncology, has announced the commencement of an underwritten public offering aimed at raising $250 million through the sale of its common stock. The ambitious initiative, disclosed on October 25, 2023, re...

Nov 5, 2025 • Medical Laboratories Industry
GH
Business Update
Incytes Hematology Breakthroughs to Take Center Stage at ASH 2025 Over 50 s Accepted,

Incyte Set to Shine at ASH Annual Meeting 2025 with Over 50 Accepted s Focused on Advancements in Hematology Incyte Corporation (Nasdaq: INCY), a leading biopharmaceutical company, has announced the acceptance of over 50 summaries (abstracts) for presentation at the Annual Meeting of the American Society of Hematology (ASH) set to be held from December 6 ...

Nov 5, 2025 • Medical Laboratories Industry
INCY
Business Update
Nateras Breakthrough in Blood-Based Screening PROCEED-CRC Trial Highlights Promising Sensitivity and Specificity for...

Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity In a significant advancement in the field of precision medicine, Natera, Inc. (NASDAQ: NTRA) has announced promising results from its recent phase of the PROCEED-CRC trial, which is assessing a novel blood-based screening t...

Oct 29, 2025 • Medical Laboratories Industry
NTRA
Business Update
Incyte Breaks New Ground in Oncology Promising Clinical Results and Robust Financial Growth Propel Cancer Innovati...

Wilmington, Delaware Incyte Corporation (Nasdaq: INCY) has unveiled pivotal clinical results from the Phase 1 study of its bispecific antibody TGFR2PD-1 (INCA33890), aimed at targeting advanced colorectal cancer, alongside a breakthrough oral inhibitor of KRAS G12D mutations (INCB161734) for advanced pancreatic ductal adenocarcinoma (PDAC). These devel...

Oct 20, 2025 • Medical Laboratories Industry
INCY
Clinical Study
Detailed Results fromPIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate ...

Pioneering Progress in Breast Cancer Treatment: Gedatolisib Shows Potential as a Game Changer: Recent findings from Celcuity Inc. regarding the efficacy of gedatolisib in treating hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), advanced breast cancer (ABC) have shown promising results. This article interprets t...

Oct 20, 2025 • Medical Laboratories Industry
CELC
Business Update
Natera’s IMvigor011 Trial Shows 41% Survival Improvement for Bladder Cancer Patients, Reinforcing Signatera...

In a groundbreaking development for bladder cancer treatment, Natera, Inc. (NASDAQ: NTRA), a pioneer in cell-free DNA and precision medicine, has announced compelling results from the randomized, double-blind, phase 3 IMvigor011 clinical trial focusing on muscle-invasive bladder cancer (MIBC). The trial showcased a remarkable 41% improvement in overall su...

Oct 20, 2025 • Medical Laboratories Industry
NTRA
Business Update
GE HealthCare Navigates the Future of Medicine with Groundbreaking Innovations in Anesthesia and Imaging,

How GE HealthCare is Pioneering the Future of Anesthesia and Imaging: Innovations from ANESTHESIOLOGY 2025 and BeyondAs the healthcare landscape continues to evolve, the importance of integrating advanced technologies to enhance patient care and environmental sustainability has never been clearer. At the forefront of this transformation is GE HealthCare,...

Oct 13, 2025 • Medical Laboratories Industry
GEHC
Business Update
Transcending Boundaries in Transplant Medicine CareDxs Cutting-Edge Innovations Pave a New Era of Precision,

Revolutionizing Transplant Medicine: CareDx s Breakthrough Innovations at the Forefront In the rapidly evolving world of precision medicine, CareDx, Inc. stands as a beacon of transformative potential and groundbreaking innovation, particularly in the field of organ transplantation. At the forefront of this evolution, CareDx has made significant advanceme...

Oct 7, 2025 • Medical Laboratories Industry
CDNA
Business Update
Harnessing Health Insight WHOOP and Quest Diagnostics Redefine Personal Wellness Monitoring,

The Future of Health Monitoring: WHOOP Partners with Quest Diagnostics for Clinical Lab Testing In a rapidly evolving landscape of health and wellness technology, WHOOP has carved out a unique niche by focusing on human performance enhancement through behavioral insights derived from wearable technology. The company has now taken a significant leap forwar...

Sep 18, 2025 • Medical Laboratories Industry
DGX
Business Update
Innovative Clinical Trial Paves the Way for ctDNA-Guided Treatment in Breast Cancer

In a pioneering leap for precision oncology, Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics, has announced a promising collaboration with a renowned team from Yale Cancer Center. Together, they are embarking on an ambitious clinical trial aimed at demonstrating the transformative potential of circulating tumor DNA (ctDNA) in guiding breast...

Sep 11, 2025 • Medical Laboratories Industry
PSNL
Business Update
Exact Sciences Unveils Cancerguard A Game-Changer in Multi-Cancer Detection During Significant Revenue Surge,

Exact Sciences Launches Groundbreaking Cancerguard Test: Pioneering Multi-Cancer Early Detection Amidst Revenue GrowthIn a significant advancement within the cancer diagnostics landscape, Exact Sciences Corp. (Nasdaq: EXAS), headquartered in Madison, Wisconsin, has officially launched Cancerguard, a cutting-edge multi-cancer early detection (MCED) blood ...

Sep 10, 2025 • Medical Laboratories Industry
EXAS
Business Update
Genomic Endeavours Veracytes Advances and Challenges in Thyroid Cancer Diagnostics,

Unveiling Genomic Insights: Veracyte s Prominent Role at the 2025 American Thyroid Association Annual Meeting In South San Francisco, a locus of innovation for oncology diagnostics, Veracyte, Inc. (Nasdaq: VCYT) prepares to take centre stage at the 2025 American Thyroid Association (ATA) Annual Meeting. This reputable congregation, scheduled from Septembe...

Sep 9, 2025 • Medical Laboratories Industry
VCYT
Business Update
Evolving Lung Cancer Treatment Personalis Unveils Landmark Findings in Neoadjuvant Therapy

In a significant advancement for oncology, Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomic solutions, has unveiled pivotal new data from a landmark phase 3 clinical trial, NeoADAURA, in collaboration with AstraZeneca. This groundbreaking research identifies Personalis’ NeXT Personal molecular residual disease (MRD) test as a powerful tool ...

Sep 4, 2025 • Medical Laboratories Industry
PSNL
Business Update
Nateras Signatera Test Joins Phase III ARCHER Trial in Bladder Cancer Amidst Financial Challenges

Natera Inc. (NASDAQ: NTRA), a leading entity in the realm of cell-free DNA and precision medicine, has announced a significant progression in its clinical research with the activation of the NRG Oncology trial, ARCHER (NRG-GU015). This landmark study aims to explore innovative treatment avenues in muscle-invasive bladder cancer (MIBC) by evaluating the ef...

Aug 29, 2025 • Medical Laboratories Industry
NTRA
Product Service News
Celcuity Prepares for Crucial NDA Submission of Gedatolisib Amid Financial Hurdles in Competitive Oncology S...

In a significant development for cancer treatment, Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focusing on the development of targeted therapies for oncology, announced its plan to initiate a New Drug Application (NDA) submission for its investigational drug, gedatolisib. This submission is for the treatment of hormone receptor-po...

Aug 28, 2025 • Medical Laboratories Industry
CELC
Business Update
Transforming Transplant Care How CareDxs Innovative Research is Pioneering Precision Medicine for Organ Recipients,

Utilizing Precision Medicine: CareDx s Innovative Studies Transforming Transplant OutcomesIn the evolving landscape of transplant medicine, precision tools are steadily emerging as pivotal in improving patient care and outcomes. Recent studies published by CareDx, Inc., a leader in precision medicine for transplant patients, underscore the significant im...

Aug 6, 2025 • Medical Laboratories Industry
CDNA
Business Update
CareDx Soars at World Transplant Congress A Pioneering Force in Precision Medicine

In the realm of transplant diagnostics, CareDx, Inc., headquartered in Brisbane, California, has emerged as a trailblazer, showcasing its commitment to precision medicine with impressive results at the 2025 World Transplant Congress (WTC). With over 40 abstracts and 16 oral presentations presented by independent research teams, CareDx has reinforced its r...

Aug 1, 2025 • Medical Laboratories Industry
CDNA
Business Update
GE HealthCare Leads the AI Revolution in Medical Technology with Record FDA Authorizations,

GE HealthCare s AI Prowess Fuels Innovation and Market Leadership In an era where artificial intelligence is revolutionizing industries, GE HealthCare stands as a testament to innovation and strategic foresight. For the fourth consecutive year, the company has topped the Food and Drug Administration s (FDA) list for AI-enabled medical device authorization...

Jul 23, 2025 • Medical Laboratories Industry
GEHC
Business Update
Navigating Growth and Challenges Fulgent Genetics CE Mark Approval and Financial Performance

In an exciting development for Fulgent Genetics, Inc. (NASDAQ: FLGT), the company has received CE certification under the European Union s In Vitro Diagnostic Regulation (EU IVDR) 2017/746 for its germline next-generation sequencing (NGS) system, including the FulgentExome and Fulgent Pipeline Manager (PLM). This move signifies a promising new chapter for...

Jul 19, 2025 • Medical Laboratories Industry
FLGT
Merger and Acquisition
RadNet Expands Horizons: Acquisition of iCAD Sets New Standards in AI-Powered Breast Health Solutions

RadNet Expands Horizons: Acquisition of iCAD Sets New Standards in AI-Powered Breast Health SolutionsLOS ANGELES, July 17, 2025 — In a significant advancement for the healthcare sector, RadNet, Inc. (NASDAQ: RDNT), a distinguished leader in diagnostic imaging services and digital health solutions, has officially completed the acquisition of iCAD, Inc. (...

Jul 17, 2025 • Medical Laboratories Industry
RDNT
Business Update
Personalis and Tempus Expand Collaboration to Introduce Advanced Cancer Recurrence Testing for Colorectal Cancer Pa...

Personalis and Tempus Expand Collaboration to Introduce Advanced Cancer Recurrence Testing for Colorectal Cancer PatientsIn a significant advancement for oncology diagnostics, Personalis, Inc. (Nasdaq: PSNL) has announced the expansion of its strategic collaboration with Tempus AI, Inc. (Nasdaq: TEM). This partnership now includes the development of cutt...

Jul 10, 2025 • Medical Laboratories Industry
PSNL
Business Update
Revolutionizing Colorectal Cancer Care Medicare Coverage for Exact Sciences MRD Test Opens New Avenues

In a significant advancement for colorectal cancer (CRC) patients, Exact Sciences Corp., a leading player in cancer diagnostics, recently announced that its Oncodetect molecular residual disease (MRD) test will now be covered by Medicare. This decision, made through the Centers for Medicare and Medicaid Services (CMS) Molecular Diagnostic Services Program...

Jul 9, 2025 • Medical Laboratories Industry
EXAS
Business Update
Nateras Intellectual Property A Strategic Advantage in the Growing Genetic Testing Market,

In the fast-paced world of genetic testing, Natera, Inc. (NASDAQ: NTRA) has taken significant steps to solidify its position as a leader in the field. The Austin-based company recently announced the issuance of a new patent from the U.S. Patent and Trademark Office that relates to the testing of single nucleotide variants in circulating-tumor DNA (ctDNA)....

Jun 14, 2025 • Medical Laboratories Industry
NTRA
Business Update
Incytes Retifanlimab Shows Promise in Phase 3 Trial for Anal Canal Cancer, While Financial Performance Outpaces Comp...

Incyte s Advancements in Cancer Treatment: Promising Phase 3 Data for Retifanlimab and Strong Revenue Growth Amidst Competitive ChallengesIn the ever-evolving landscape of oncology, few developments spark as much interest as groundbreaking clinical trial results. Incyte Corporation (Nasdaq: INCY) has recently captured attention with the release of pivota...

Jun 13, 2025 • Medical Laboratories Industry
INCY

Decision Framework & Data Access

Power onboarding, benchmarking, and quantitative analysis with institutional-grade datasets structured for direct integration into financial models and risk frameworks.

  • Industry benchmarking datasets (valuation, growth, profitability)
  • Designed for quant models, AML/KYC validation & onboarding workflows
  • Consistent time-series structure (Quarterly, TTM, Annual)
  • Coverage across 100+ industries and 20+ years of history
CSV - SFTP - REST API - Daily Updates - Integration-ready for Python, R & BI tools